BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 8 filers reported holding BIO-TECHNE CORP in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $17,584 | +169.9% | 258,326 | +223.7% | 0.03% | +233.3% |
Q2 2023 | $6,514 | -80.9% | 79,800 | -82.6% | 0.01% | -80.0% |
Q1 2023 | $34,105 | -1.6% | 459,700 | +9.9% | 0.04% | -4.3% |
Q4 2022 | $34,677 | -100.0% | 418,400 | +54.4% | 0.05% | -56.9% |
Q3 2022 | $76,948,000 | +51.8% | 270,944 | +85.3% | 0.11% | +81.7% |
Q2 2022 | $50,679,000 | +262.3% | 146,200 | +352.6% | 0.06% | +275.0% |
Q1 2022 | $13,987,000 | +193.8% | 32,300 | +251.1% | 0.02% | +166.7% |
Q4 2021 | $4,760,000 | +263.9% | 9,200 | +240.7% | 0.01% | +200.0% |
Q3 2021 | $1,308,000 | -66.2% | 2,700 | -68.6% | 0.00% | -60.0% |
Q2 2021 | $3,872,000 | -71.6% | 8,600 | -75.9% | 0.01% | -70.6% |
Q1 2021 | $13,617,000 | -73.8% | 35,652 | -78.3% | 0.02% | -70.2% |
Q4 2020 | $52,066,000 | -33.0% | 163,963 | -47.7% | 0.06% | -26.9% |
Q3 2020 | $77,657,000 | -24.6% | 313,475 | -19.7% | 0.08% | -12.4% |
Q2 2020 | $103,034,000 | +11.6% | 390,175 | -19.9% | 0.09% | -1.1% |
Q1 2020 | $92,311,000 | -16.9% | 486,820 | -3.8% | 0.09% | +5.9% |
Q4 2019 | $111,105,000 | +0.1% | 506,151 | -10.8% | 0.08% | -9.6% |
Q3 2019 | $110,968,000 | +12.7% | 567,120 | +20.1% | 0.09% | +8.0% |
Q2 2019 | $98,474,000 | +1.2% | 472,320 | -3.7% | 0.09% | -2.2% |
Q1 2019 | $97,353,000 | +8.3% | 490,320 | -21.1% | 0.09% | -9.2% |
Q4 2018 | $89,903,000 | -0.7% | 621,220 | +40.0% | 0.10% | +5.4% |
Q3 2018 | $90,564,000 | -22.7% | 443,700 | -43.4% | 0.09% | +45.3% |
Q2 2018 | $117,152,000 | +109.5% | 784,100 | +111.7% | 0.06% | +4.9% |
Q1 2018 | $55,930,000 | +21.3% | 370,300 | +4.0% | 0.06% | +19.6% |
Q4 2017 | $46,120,000 | +55.9% | 356,000 | +45.5% | 0.05% | +45.7% |
Q3 2017 | $29,582,000 | +71.2% | 244,700 | +66.3% | 0.04% | +59.1% |
Q2 2017 | $17,284,000 | -9.8% | 147,100 | -22.0% | 0.02% | -18.5% |
Q1 2017 | $19,171,000 | +2.7% | 188,600 | +3.9% | 0.03% | -10.0% |
Q4 2016 | $18,664,000 | +18.8% | 181,500 | +26.5% | 0.03% | +7.1% |
Q3 2016 | $15,713,000 | +250.1% | 143,500 | +260.6% | 0.03% | +211.1% |
Q2 2016 | $4,488,000 | -54.4% | 39,800 | -61.8% | 0.01% | -52.6% |
Q1 2016 | $9,840,000 | -31.6% | 104,100 | -34.9% | 0.02% | -38.7% |
Q4 2015 | $14,382,000 | -36.6% | 159,800 | -34.9% | 0.03% | -42.6% |
Q3 2015 | $22,690,000 | +17.9% | 245,400 | +25.6% | 0.05% | +22.7% |
Q2 2015 | $19,241,000 | -31.8% | 195,400 | -30.5% | 0.04% | -26.7% |
Q1 2015 | $28,192,000 | -42.1% | 281,100 | -46.6% | 0.06% | -48.7% |
Q4 2014 | $48,667,000 | – | 526,700 | – | 0.12% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
Westwind Capital | 27,946 | $9,687,000 | 3.17% |
MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |